Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis


Por: Stojanovic, I, Dimitrijevic, M, Vives-Pi, M, Mansilla, MJ, Pujol-Autonell, I, Rodriguez-Fernandez, S, Palova-Jelinkova, L, Funda, DP, Gruden-Movsesijan, A, Sofronic-Milosavljevic, L, Hilkens, CMU, Caceres, EM and Miljkovic, D

Publicada: 1 ene 2017
Resumen:
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.

Filiaciones:
Stojanovic, I:
 Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Belgrade, Serbia

Dimitrijevic, M:
 Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Belgrade, Serbia

:
 Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Cellular Biol Physiol & Immunol, Immunol Div, Campus Can Ruti, Barcelona 08916, Spain

 ISCIII, CIBER Diabet & Assoc Metab Dis CIBERDEM, Madrid 28029, Spain

:
 Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Cellular Biol Physiol & Immunol, Immunol Div, Campus Can Ruti, Barcelona 08916, Spain

Pujol-Autonell, I:
 Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Cellular Biol Physiol & Immunol, Immunol Div, Campus Can Ruti, Barcelona 08916, Spain

:
 Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Cellular Biol Physiol & Immunol, Immunol Div, Campus Can Ruti, Barcelona 08916, Spain

Palova-Jelinkova, L:
 SOTIO As, Prague, Czech Republic

Funda, DP:
 CAS, Inst Microbiol, Dept Immunol & Gnotobiol, Vvi, Prague, Czech Republic

Gruden-Movsesijan, A:
 Univ Belgrade, Inst Applicat Nucl Energy INEP, Dept Immunol & Immunoparasitol, Belgrade, Serbia

Sofronic-Milosavljevic, L:
 Univ Belgrade, Inst Applicat Nucl Energy INEP, Dept Immunol & Immunoparasitol, Belgrade, Serbia

Hilkens, CMU:
 Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

:
 Univ Autonoma Barcelona, Germans Trias & Pujol Univ Hosp, Dept Cellular Biol Physiol & Immunol, Immunol Div, Campus Can Ruti, Barcelona 08916, Spain

Miljkovic, D:
 Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Belgrade, Serbia
ISSN: 13816128





Current Pharmaceutical Design
Editorial
Bentham Science Publishers, EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES, Emiratos Arabes Unidos
Tipo de documento: Review
Volumen: 23 Número: 18
Páginas: 2623-2643
WOS Id: 000405678800007
ID de PubMed: 28201972

MÉTRICAS